AprilBio Co.,Ltd.

A397030

KR7397030008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
15,160 ^KRW	+0.86%		+1.07%	-10.03%

2023	AprilBio Co.,Ltd.(KOSDAQ:A397030) added to S&P Global BMI Index	CI
2023	AprilBio Co.,Ltd. announced that it has received KRW 15 billion in funding from Lake Asset Management Ltd., Korea Investment & Securities Co., Ltd., Ehyun Asset Management Co., Ltd.	CI

AprilBio Co.,Ltd. announced that it has received KRW 15 billion in funding from Lake Asset Management Ltd., Korea Investment & Securities Co., Ltd., Ehyun Asset Management Co., Ltd.

April 20, 2023

On April 21, 2023, AprilBio Co.,Ltd. closed the transaction.

Latest news about AprilBio Co.,Ltd.

AprilBio Co.,Ltd.(KOSDAQ:A397030) added to S&P Global BMI Index	23-09-18	CI
AprilBio Co.,Ltd. announced that it has received KRW 15 billion in funding from Lake Asset Management Ltd., Korea Investment & Securities Co., Ltd., Ehyun Asset Management Co., Ltd.	23-04-20	CI
AprilBio Co.,Ltd. announced that it expects to receive KRW 15 billion in funding from Lake Asset Management Ltd., Korea Investment & Securities Co., Ltd., Ehyun Asset Management Co., Ltd.	23-04-18	CI
AprilBio Co.,Ltd. has completed an IPO in the amount of KRW 20.736 billion.	22-07-18	CI
AprilBio Co.,Ltd. has filed an IPO.	21-11-02	CI
Lundbeck Receives Exclusive Rights to APB-A1, an Innovative Phase I-Ready Bio-Therapeutic for the Treatment of Neuroimmune Diseases from AprilBio	21-10-14	CI
APRILBIO co., Ltd. announced that it has received KRW 10 billion in funding from Yuhan Corporation	21-03-22	CI

AprilBio Co Ltd is a Korea-based company primarily engaged in the biological drug development business. The Company is primarily engaged in the bio-innovative new drug research and development (R&D) business such as antibody therapeutics and long-acting recombinant protein pharmaceuticals.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15,160 KRW

Average target price

27,000 KRW

Spread / Average Target

+78.10%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
APRILBIO CO.,LTD.	-10.03%	239M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.75%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.84%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs

AprilBio Co.,Ltd.

Equities

A397030

KR7397030008

Biotechnology & Medical Research

AprilBio Co.,Ltd. announced that it has received KRW 15 billion in funding from Lake Asset Management Ltd., Korea Investment & Securities Co., Ltd., Ehyun Asset Management Co., Ltd.

Latest news about AprilBio Co.,Ltd.

Chart AprilBio Co.,Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs